查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370888

地中海型貧血診斷市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型（完整血球測試、血紅蛋白測試、缺鐵測試、DNA 測試等）、最終用戶、按地區和競賽

Thalassemia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Complete Blood Cell Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others), By End User, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

由於醫療保健支出的增加、政府的支持性政策、診斷技術的進步、對地中海貧血的認知不斷提高以及地中海貧血患病率的增加，預計到 2028 年，全球地中海貧血診斷市場將大幅成長。

地中海貧血是一種遺傳性血液疾病，會影響血紅蛋白的產生，而血紅素對於體內氧氣的運輸至關重要。地中海貧血有兩種主要類型：α地中海貧血和BETA地中海貧血。

全球地中海貧血診斷市場的推動因素是全球地中海貧血盛行率不斷上升，以及人們對該疾病的認知不斷提高。根據Cureus發表的報告，全球約1.5%的人口，約1億人，帶有B地中海貧血基因，其中東南亞、中東和地中海地區患病率最高。地中海貧血診斷市場包括地中海貧血篩檢、診斷和監測的測試。這些測試包括全血球計數、血紅蛋白電泳、DNA 分析等。由於擴大採用先進的診斷技術（例如 PCR 和基因檢測），全球地中海貧血診斷市場預計將成長，這些技術在檢測地中海貧血方面提供了更高的準確性和靈敏度。

市場概況
預測期 2024-2028
2022 年市場規模 52009萬美元
2028 年市場規模 7.3288億美元
2023-2028 年年複合成長率 5.86%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

從地理上看，亞太地區和中東和北非地區由於地中海貧血的高盛行率而主導了地中海貧血診斷市場。然而，由於人們對地中海貧血的認知不斷提高以及先進診斷技術的可用性，其他地區的市場也在成長，例如北美和歐洲，尤其是土耳其。因此，預計全球地中海貧血診斷市場的需求將在預測期內上升。

人們對地中海貧血的認知不斷提高，推動了全球地中海貧血診斷市場的需求

地中海貧血是一種遺傳性血液疾病，影響全世界數百萬人。它是由控制血紅蛋白產生的基因突變引起的，血紅蛋白是一種負責在血液中攜帶氧氣的蛋白質。地中海貧血患者產生的健康紅血球較少，因此貧血、疲勞和其他併發症的風險較高。這種疾病在地中海、中東和亞洲週邊國家尤其普遍，這些國家的基因突變更為常見。據估計，全球每年約有 30-40 萬名兒童出生時患有遺傳性 Hb 疾病，其中約 8,000 萬名兒童是 B 地中海貧血的轉移者。

有利的政府政策是推動地中海貧血診斷市場成長的關鍵驅動力

支持性政府政策一直是影響全球地中海貧血診斷市場需求的驅動力。世界各國政府已經認知到需要解決地中海貧血對其醫療保健系統日益增加的負擔，並已採取措施支持地中海貧血診斷測試的開發和使用。地中海貧血患者產生的健康紅血球較少，發生貧血、疲勞和其他併發症的風險較高。這種疾病在地中海、中東和亞洲週邊國家尤其普遍，這些國家的基因突變更為常見。

政府支持政策影響地中海貧血診斷測試需求的主要方法是透過資金和投資。各國政府投資研發新的和改進的地中海貧血診斷測試，從而開發出更準確、更有效的測試。各國政府也提供資金以增加診斷測試的機會，特別是在地中海貧血盛行率較高的發展中國家。例如，“婚前檢查”，一對即將結婚的夫婦需要接受多項檢查，以檢查遺傳性血液疾病（例如鐮狀細胞性貧血和地中海貧血和鐮狀細胞性貧血）和傳染病（例如乙型肝炎、C型肝炎、和愛滋病毒/愛滋病）在沙烏地阿拉伯。

各國政府也實施了要求對地中海貧血進行強制篩檢的政策。例如，在許多國家，新生兒都會接受地中海貧血篩檢，以便及早發現患有這種疾病的人並提供適當的治療。這增加了對地中海貧血診斷測試的需求，並導致對準確和可靠的測試的更大需求。患有嚴重地中海貧血（如重型地中海貧血）的兒童通常會在 5 歲以下死亡，地中海貧血患者的平均壽命約為 30 歲，主要發生在資源嚴重受限的國家。

此外，政府的支持性政策有助於提高人們對地中海貧血以及早期診斷和治療重要性的認知。各國政府發起了提高意識運動，教育大眾了解地中海貧血及其對個人和社會的影響。這導致尋求地中海貧血診斷測試的人數增加，並有助於減少與疾病相關的恥辱感。

診斷技術的進步正在推動地中海貧血診斷市場成長的需求

診斷技術的進步在推動市場上地中海貧血診斷測試的需求方面發揮了重要作用。這些進步導致了更準確、更有效的測試的發展，從而提高了地中海貧血患者的護理品質。基因檢測徹底改變了許多遺傳性疾病的診斷和治療，包括地中海貧血。它涉及分析個體的 DNA，以識別與疾病相關的特定基因突變。這種類型的測試非常準確，即使在沒有表現出症狀的個體中也可以檢測出地中海貧血。即時檢測 (POCT) 可以在床邊或醫生辦公室快速診斷疾病。 POCT 設備是攜帶式的，可以在幾分鐘內提供結果，減少實驗室檢測的需要並改善患者護理。

市場區隔

全球地中海貧血診斷市場根據類型、最終用戶和地區進行細分。根據類型，市場分為全血細胞 (CBC) 測試、血紅蛋白測試、缺鐵測試、DNA 測試等。根據最終用戶，市場分為醫院和診所、診斷實驗室等。依地區分類，市場分為北美、歐洲、亞太地區、南美、中東和非洲。

公司簡介

Hybribio Limited、Oasis Diagnostics Corporation、ViennaLab Diagnostics GmbH、GENETEK BIOPHARMA GmbH、Devyser Diagnostics AB、亞能生物科學（深圳）有限公司、BioLab Diagnostics India Private Limited、NPT Co. Ltd 和 Bio-Rad Laboratories, Inc.是全球地中海貧血診斷市場的一些關鍵參與者。

報告範圍：

在本報告中，除了產業趨勢外，全球地中海貧血診斷市場還分為以下幾類，詳細資訊如下：

地中海貧血診斷市場，依類型：

  • 全血球 (CBC) 測試
  • 血紅素測試
  • 缺鐵測試
  • 脫氧核糖核酸測試
  • 其他

地中海貧血診斷市場，依最終用戶分類：

  • 醫院和診所
  • 診斷實驗室
  • 其他

地中海貧血診斷市場，按地區：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 亞太
  • 中國
  • 印度
  • 馬來西亞
  • 泰國
  • 越南
  • 南美洲
  • 巴西
  • 阿根廷
  • 中東和非洲
  • 埃及
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 土耳其
  • 科威特
  • 卡達
  • 巴林

競爭格局

  • 公司簡介：全球地中海貧血診斷市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：COVID-19 對全球地中海貧血診斷市場的影響

第 6 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究類型分類的管道細目
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 7 章：全球地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（全血細胞 (CBC) 測試、血紅蛋白測試、缺鐵測試、DNA 測試等）
    • 按最終使用者（醫院和診所、診斷實驗室、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按類型
    • 按最終用戶
    • 按地區

第 8 章：北美地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 9 章：歐洲地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利

第 10 章：亞太地區地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 馬來西亞
    • 泰國
    • 越南

第 11 章：南美洲地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷

第 12 章：中東和非洲地中海貧血診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 埃及地中海貧血診斷
    • 南非地中海貧血診斷
    • 沙烏地阿拉伯地中海貧血診斷
    • 阿拉伯聯合大公國地中海貧血診斷
    • 土耳其地中海貧血診斷
    • 科威特地中海型貧血診斷
    • 卡達地中海貧血診斷
    • 巴林地中海貧血診斷

第 13 章：市場動態

  • 促進要素
  • 挑戰

第 14 章：市場趨勢與發展

  • 產品發布
  • 併購
  • 最近的發展

第 15 章：全球地中海貧血診斷市場：SWOT 分析

第16章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第17章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Hybribio Limited
    • Oasis Diagnostics Corporation
    • ViennaLab Diagnostics GmbH
    • GENETEK BIOPHARMA GmbH
    • Devyser Diagnostics AB
    • Yaneng BIOscience (Shenzhen) Co., Ltd.
    • BioLab Diagnostics India Private Limited
    • NPT Co. Ltd.
    • Bio-Rad Laboratories, Inc.

第 18 章：策略建議

第 19 章：關於我們與免責聲明

簡介目錄
Product Code: 15063

Global Thalassemia Diagnostic market is anticipated to grow considerably in the forecast period of 2028 due to rising healthcare expenditure, supportive government policy, advancements in diagnostic technologies, growing awareness about thalassemia, and increasing prevalence of thalassemia.

Thalassemia is a genetic blood disorder that affects the production of hemoglobin, which is essential for the transportation of oxygen in the body. There are two main types of thalassemia: alpha thalassemia and beta thalassemia.

The market for global thalassemia diagnostics is driven by the increasing prevalence of thalassemia worldwide, coupled with growing awareness among people about the disease. According to a published report by Cureus, around 1.5% of the world's population, or about 100 million people, carry the genes for B-thalassemia, with the highest prevalence in Southeast Asia, the Middle East, and the Mediterranean region. The market for thalassemia diagnostics includes tests for screening, diagnosis, and monitoring of thalassemia. These tests include complete blood count, hemoglobin electrophoresis, DNA analysis, and others. The global thalassemia diagnostics market is expected to grow due to the increasing adoption of advanced diagnostic technologies, such as PCR and genetic testing, which offer higher accuracy and sensitivity in detecting thalassemia.

Market Overview
Forecast Period2024-2028
Market Size 2022USD520.09 Million
Market Size 2028USD732.88 Million
CAGR 2023-20285.86%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Geographically, the Asia Pacific and MENA regions dominate the thalassemia diagnostic market, owing to the high prevalence of thalassemia in the region. However, the market is also growing in other regions, such as North America and Europe especially in Turkey, due to increasing awareness about thalassemia and the availability of advanced diagnostic technologies. Therefore, it is expected that the demand for the global thalassemia diagnostic market is going to rise in the forecast period.

Growing Awareness About Thalassemia is Propelling the Demand for the Global Thalassemia Diagnostic Market

Thalassemia is a genetic blood disorder that affects millions of people worldwide. It is caused by mutations in the genes that control the production of hemoglobin, a protein that is responsible for carrying oxygen in the blood. Individuals with thalassemia produce fewer healthy red blood cells and are therefore at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where gene mutations are more usual. Globally, it is estimated that approximately 300-400 thousand children are born yearly with genetic substantial Hb diseases of which around 80 million children are transferors of B-thalassemia.

Growing awareness about thalassemia is propelling the demand for the global thalassemia diagnostic market. There is an increasing understanding of the disease among people, which has led to an increase in the number of people seeking diagnostic tests for thalassemia. The awareness has also increased the number of newborns and pregnant women being screened for thalassemia, which has further driven the demand for diagnostic tests.

The efforts of governments and healthcare organizations to educate people about the disease are one of the main drivers of the growing awareness about thalassemia. Governments around the world have launched awareness campaigns to educate people about the importance of early detection and treatment of thalassemia. These campaigns have included public service announcements, seminars, and workshops for healthcare professionals and the public. Such as Turkey Hemoglobinopathy Control Program has been initiated in 33 provinces of Turkey to screen and create awareness about B-thalassemia and its symptoms.

In addition to government initiatives, healthcare organizations, and patient advocacy groups have also played a significant role in raising awareness about thalassemia. These organizations have provided information about the disease to patients and their families, as well as to healthcare professionals. They have also offered support and resources to individuals with thalassemia and their families. The FDA or the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Beta Thalassemia drugs. Through this ODD, companies can get incentives to invest in rare disease treatments.

Another factor contributing to the growing awareness about thalassemia is the availability of information on the internet. Patients and their families can access information about the disease, including its symptoms, causes, and treatment options. The internet has also provided a platform for patient communities to connect and share their experiences, which has helped to increase awareness about the disease.

The growing awareness about thalassemia has led to an increase in the demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests are used to screen, diagnose, and monitor the disease. With increased awareness about the disease, more people are seeking diagnostic tests, which has driven the demand for thalassemia diagnostic tests. Therefore, all these factors are expected to drive the demand for the global thalassemia diagnostic market in the forecast period.

Favorable Government Policies are Key drivers that Drive the Thalassemia Diagnostic Market Growth

Supportive government policies have been a driving force in influencing the demand for the global thalassemia diagnostic market. Governments around the world have recognized the need to address the increasing burden of thalassemia on their healthcare systems and have taken steps to support the development and use of thalassemia diagnostic tests. Individuals with thalassemia produce fewer healthy red blood cells and are at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where the gene mutations are more common.

The primary method by which supportive government policies have influenced the demand for thalassemia diagnostic tests is through funding and investment. Governments have invested in research and development of new and improved diagnostic tests for thalassemia, which has led to the development of more accurate and efficient tests. Governments have also provided funding to increase access to diagnostic tests, particularly in developing countries where the prevalence of thalassemia is high. For instance, the "Premarital Screening" in which a couple planning to get married soon needs to undergo several tests to check genetic blood disorders (e.g. sickle cell anemia and thalassemia and sickle cell anemia) and infectious diseases (e.g. hepatitis B, hepatitis C, and HIV/AIDS) in Saudi Arabia.

Governments have also implemented policies that require mandatory screening for thalassemia. For example, in many countries, newborns are screened for thalassemia to identify those with the disorder early on and provide appropriate treatment. This has increased the demand for thalassemia diagnostic tests and has led to a greater need for accurate and reliable tests. Children with severe forms of thalassemia (such as thalassemia major) typically decease under 5 years of age and the average life expectancy of patients suffering from thalassemia is about 30 years, predominantly in seriously resource-constrained countries.

Furthermore, supportive government policies have helped to increase awareness about thalassemia and the importance of early diagnosis and treatment. Governments have launched awareness campaigns to educate the public about thalassemia and its impact on individuals and society. This has led to an increase in the number of people seeking diagnostic tests for thalassemia and has helped to reduce the stigma associated with the disorder.

Advancements in Diagnostic Technologies are Driving the Demand for Thalassemia Diagnostic Market Growth

Advancements in diagnostic technologies have played a significant role in driving the demand for thalassemia diagnostic tests in the market. These advancements have led to the development of more accurate and efficient tests, which have improved the quality of care for individuals with thalassemia. Genetic testing has revolutionized the diagnosis and management of many genetic disorders, including thalassemia. It involves analyzing an individual's DNA to identify specific genetic mutations associated with the disorder. This type of testing is highly accurate and can detect thalassemia even in individuals who do not exhibit symptoms. Point-of-care testing (POCT) allows for the rapid diagnosis of disease at the bedside or in the doctor's office. POCT devices are portable and can provide results in a matter of minutes, reducing the need for laboratory testing and improving patient care.

Market Segmentation

Global Thalassemia Diagnostic market is segmented based on type, end-user, and region. Based on type, the market is segmented into complete blood cell (CBC) tests, hemoglobin tests, iron deficiency tests, DNA tests, and others. Based on end-user, the market is fragmented into hospitals & clinics, diagnostic laboratories, and others. Based on region, the market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Hybribio Limited, Oasis Diagnostics Corporation, ViennaLab Diagnostics GmbH, GENETEK BIOPHARMA GmbH, Devyser Diagnostics AB, Yaneng BIOscience, Shenzhen) Co., Ltd., BioLab Diagnostics India Private Limited, NPT Co. Ltd., and Bio-Rad Laboratories, Inc. are some of the key players in the global thalassemia diagnostic market.

Report Scope:

In this report, global thalassemia diagnostic market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Thalassemia Diagnostic Market, By Type:

  • Complete Blood Cell (CBC) Test
  • Hemoglobin Test
  • Iron Deficiency Test
  • DNA Tests
  • Others

Thalassemia Diagnostic Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Thalassemia Diagnostic Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Asia-Pacific
  • China
  • India
  • Malaysia
  • Thailand
  • Vietnam
  • South America
  • Brazil
  • Argentina
  • Middle East & Africa
  • Egypt
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Kuwait
  • Qatar
  • Bahrain

Competitive landscape

  • Company Profiles: Detailed analysis of the major companies present in the global Thalassemia Diagnostic market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Diagnostics Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Thalassemia Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others)
    • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.3. By Region
    • 7.2.4. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By End User
    • 7.3.3. By Region

8. North America Thalassemia Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Thalassemia Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Canada Thalassemia Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Mexico Thalassemia Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User

9. Europe Thalassemia Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Thalassemia Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. France Thalassemia Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. United Kingdom Thalassemia Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User
    • 9.3.4. Spain Thalassemia Diagnostics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By End User
    • 9.3.5. Italy Thalassemia Diagnostics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By End User

10. Asia-Pacific Thalassemia Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Thalassemia Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. India Thalassemia Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Malaysia Thalassemia Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User
    • 10.3.4. Thailand Thalassemia Diagnostics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By End User
    • 10.3.5. Vietnam Thalassemia Diagnostics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By End User

11. South America Thalassemia Diagnostics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By End User
    • 11.2.3. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Thalassemia Diagnostics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By End User
    • 11.3.2. Argentina Thalassemia Diagnostics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By End User

12. Middle East and Africa Thalassemia Diagnostics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By End User
    • 12.2.3. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. Egypt Thalassemia Diagnostics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By End User
    • 12.3.2. South Africa Thalassemia Diagnostics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By End User
    • 12.3.3. Saudi Arabia Thalassemia Diagnostics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By End User
    • 12.3.4. UAE Thalassemia Diagnostics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Type
        • 12.3.4.2.2. By End User
    • 12.3.5. Turkey Thalassemia Diagnostics Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Type
        • 12.3.5.2.2. By End User
    • 12.3.6. Kuwait Thalassemia Diagnostics Market Outlook
      • 12.3.6.1. Market Size & Forecast
        • 12.3.6.1.1. By Value
      • 12.3.6.2. Market Share & Forecast
        • 12.3.6.2.1. By Type
        • 12.3.6.2.2. By End User
    • 12.3.7. Qatar Thalassemia Diagnostics Market Outlook
      • 12.3.7.1. Market Size & Forecast
        • 12.3.7.1.1. By Value
      • 12.3.7.2. Market Share & Forecast
        • 12.3.7.2.1. By Type
        • 12.3.7.2.2. By End User
    • 12.3.8. Bahrain Thalassemia Diagnostics Market Outlook
      • 12.3.8.1. Market Size & Forecast
        • 12.3.8.1.1. By Value
      • 12.3.8.2. Market Share & Forecast
        • 12.3.8.2.1. By Type
        • 12.3.8.2.2. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Thalassemia Diagnostics Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. Hybribio Limited
    • 17.6.2. Oasis Diagnostics Corporation
    • 17.6.3. ViennaLab Diagnostics GmbH
    • 17.6.4. GENETEK BIOPHARMA GmbH
    • 17.6.5. Devyser Diagnostics AB
    • 17.6.6. Yaneng BIOscience (Shenzhen) Co., Ltd.
    • 17.6.7. BioLab Diagnostics India Private Limited
    • 17.6.8. NPT Co. Ltd.
    • 17.6.9. Bio-Rad Laboratories, Inc.

18. Strategic Recommendations

19. About Us & Disclaimer